Pulmonologie nieuws
- Alzheimer’s Incidence and Prevalence with and without Asthma: A Medicare cohort study
- Airborne indoor allergen serine proteases and their contribution to sensitisation and activation of innate immunity in allergic airway disease
- Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials
- Gait differences between COPD and healthy controls: systematic review and meta-analysis
- Action needed on needless asthma deaths, says charity
- Ideaya Biosciences announces selection of move?forward phase 2 expansion dose for IDE397 monotherapy in MTAP?deletion squamous NSCLC
- Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis
- RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
- [Articles] The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China
- [Comment] Long COVID and SARS-CoV-2 persistence: new answers, more questions
- Rheumatoid arthritis and idiopathic pulmonary fibrosis: a bidirectional Mendelian randomisation study
- Relative Effectiveness of the MF59®?Adjuvanted Influenza Vaccine Versus High?Dose and Non?Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019–2020 US Influenza Season
- Roche's Alecensa gets US FDA approval for adjuvant treatment for people with ALK─positive early─stage lung cancer
- [Historical Review] Social histories of public health misinformation and infodemics: case studies of four pandemics
- Roche’s Alecensa approved by FDA as lung cancer treatment